Sorafenib-d3

Sorafenib-d3 (Donafenib), a deuterated compound of Sorafenib, is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively[1].

Product Specifications

CAS Number

[1130115-44-4]

Product Name Alternative

Donafenib; Bay 43-9006-d3

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Autophagy; Ferroptosis; FLT3; Raf; VEGFR

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

99.57

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=NC=CC(OC2=CC=C(NC(NC3=CC=C(Cl)C(C(F)(F)F)=C3)=O)C=C2)=C1)NC([2H])([2H])[2H]

Molecular Formula

C21H13D3ClF3N4O3

Molecular Weight

467.84

Precautions

H302, H315, H319, H335

References & Citations

[1]Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64 (19) :7099-109.